Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc (NQ: VRCA )

6.800 +0.040 (+0.59%)
Streaming Delayed Price Updated: 11:29 AM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Outlook For Verrica Pharmaceuticals
Via Benzinga
7 Analysts Have This to Say About Verrica Pharmaceuticals
Via Benzinga
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
From Kahn Swick & Foti, LLC
Via Business Wire
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
Giving the bears a rough time can yield massive gains for contrarians, thus drawing attention to these potential short-squeeze stocks. 
Via InvestorPlace
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Top 4 Health Care Stocks That May Crash This Month
As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Insiders Buying Pfizer And 3 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
With Verrica Pharmaceuticals releasing positive Phase 3 trial results for a skin disease therapeutic, VRCA stock skyrocketed in response. 
Via InvestorPlace
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) Near the Top of Equities by Percentage Gain on 12/15
Via Investor Brand Network
Why Quanex Building Products Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth-quarter financial results. Quanex Building Products shares fell 10.7% to... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Is Skin Disease-Focused Verrica Pharmaceuticals Stock Trading Higher Today?
Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) development and commercialization partner, Torii Pharmaceutical Co Ltd, reported topline results from its Phase 3 trial of TO-208 (referred to as VP-102 and... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.